👇This is why NHS is great - free at the point of care and no worries about financial toxicity!

A lot of people are dragging this person. The knee jerk reaction of “92% coverage?! That’s amazing! Why are you complaining. Leave the country.” This shows how low the bar has been set for health insurance coverage in the US. Let’s put on our empathy hats for a moment.

Imagine

📢Are you a patient, in the East of England, who has received radiotherapy in the past 5 years? Would you like to join our network Patient Participation Group to help shape the future of radiotherapy services? If so please get in touch East of England Cancer Alliance Rad Chat

👇Outstanding leadership Alison Tree 💙!

Re #PACE trials

❌ No spin

✅ Hard facts
👉Transient ⬆️ GI tox with SABR
👉Patients love 5# 🙏
👉Transformative in prostate #SABR
👉Run by reputed team, supported by huge 🇬🇧 network

🇬🇧 will continue to lead prostate #SABR

The Radiotherapy Board also published the ESTRO-HERO report, which estimates the cost of radiotherapy to the NHS for the first time.

The report shows how radiotherapy benefits tens of thousands of patients each year at a relatively modest expense 👇

rcr.ac.uk/news-policy/po…

Yup same operation used for over 40 years. The robot makes ergonomic differences but data suggests its surgeon volume (not the machine) that improves outcomes.

Cf RT for #ProstateCa has been revolutionized.
1990’s: 33+ tx, >50+ BF
2018: 5 tx, 3.5% BF
2028: 2 tx, 🟰BF, ⬆️ QOL?

Nice editorial by Deep Chakrabarti Chris Parker!

🔑 low cost and tox , easy access to prostate RT

🤔 Why we are so focussed on OS benefit in #radonc ? Perhaps we set our bar too high as #radonc treatments are mostly curative?

We need level playing field!

Personalised cancer vaccine trial in melanoma is open ⁦Cambridge University Hospitals NHS ⁦AddenbrookesOncology⁩, led by Dr Corrie⁩! ⁦⁩ Brent O'Carrigan⁩ ⁦NIHR CRN East of England⁩ 👉British man tests first personalised melanoma vaccine ⁦⁦BBC News (UK)⁩ bbc.co.uk/news/health-68…

Missing #BTOG24 ? Don’t worry, we’ve got plenty of key highlights and coverage over at VJOncology.com!

Click here ➡️vjoncology.com/event/btog-2024

BTOG #LungCancer #LCSM #NSCLC #SCLC #Mesothelioma

📢 Calling all breast cancer clinicians in the UK and Internationally! Please participate in our survey on the use of SBRT in oligometastatic breast cancer. Your insights will help shape future clinical trial design!💫

Anna Kirby
#BreastCancer #SBRT
 
forms.office.com/e/DVp7uQYrPj

In car😊Obviously not an exotic place, but rehydrating after a long day at work post #BTOG24 BTOG

BTOG is 20 this year! In our latest 'BTOG Does...' podcast Tom Newsom-Davis
talks to Sanjay Popat about 20 years of BTOG. Listen at btog.org/resources/btog… #btogpodcast

🥰

#BTOG24

That’s it! As our 22nd annual conference closes, we’d like to thank our speakers to sharing their valuable expertise, our hosts, sponsors and all of our amazing attendees. See you here again next year for #BTOG25 ! #BTOG24 #LCSM

Save the dates 3-5 March 2025.

Next up Matthew Hatton gives an overview of providing ontological treatments to patients with ILD and lung cancer 🫁

Our own local experience with radiotherapy and ILD published last year in BJR Journals

❓Is a national database needed?

🔗 academic.oup.com/bjro/article/5…

#BTOG24 BTOG

#HIT -Meso trial (proton beam therapy #radonc ) is coming to a 🇬🇧 cancer centre/unit near you!

Crispin Hiley Asthma + Lung UK

#BTOG24 @btog Stage III NSCLC - Resect or Not? Nice summary by Mariana Brandao #lcsm #radonc

#BTOG24 BTOG #TOURIST #HALT2 trials meeting

Exceptional engagement from 🇬🇧 #radonc colleagues & EORTC University of Zurich Matthias Guckenberger

Matthew Hatton David Woolf Fiona McDonald

Wonderful to listen to Paul van Schil IASLC president, discuss TNMv9. NSCLC: Highlights N2 split into N2a & N2b: by station not node. M1c split to M1c1, M1c2 by organ system.

In Meso cT depends on 3 T measurements and fissure measure. This will be complex to implement! #BTOG24